A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Opioid Dependence

Interventions

DRUG

Probuphine (buprenorphine implant)

Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)

DRUG

Sublingual Buprenorphine

16 mg/day, QD

Trial Locations (1)

Segal Institute For Clinical Research, Fort Lauderdale